We fell quite short of Inderes’ expectations. I just have to say that the communication regarding Remeo never ceases to be annoying. Once again, nothing regarding its revenue. Apparently, it hasn’t been sold off yet, then?
My own predictions went out the window that by H1 2026 at the latest, things would take off in such a way that there would be no more need for excuses. Now the story is still the same; high expectations based on the product’s clinical superiority. Retec gonna retec.